IMUX Insider Trading

Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $100,395.00
Insider Selling (Last 12 Months): $0.00

Immunic Insider Trading History Chart

This chart shows the insider buying and selling history at Immunic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Immunic Share Price & Price History

Current Price: $1.20
Price Change: Price Decrease of -0.04 (-3.23%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for IMUX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.20Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Immunic (NASDAQ:IMUX)

51.82% of Immunic stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMUX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.29Mbought$8.13MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
Immunic logo
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More on Immunic

Today's Range

Now: $1.20
Low: $1.18
High: $1.28

50 Day Range

MA: $1.08
Low: $0.94
High: $1.26

52 Week Range

Now: $1.20
Low: $0.92
High: $2.11

Volume

653,857 shs

Average Volume

604,174 shs

Market Capitalization

$108.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Who are the company insiders with the largest holdings of Immunic?

Immunic's top insider shareholders include:
  1. Richard Alan Rudick (Director)
  2. Glenn Whaley (CFO)
Learn More about top insider investors at Immunic.

Who are the major institutional investors of Immunic?

Immunic's top institutional shareholders include:
  1. Janus Henderson Group PLC — 2.99%
  2. Focus Partners Wealth — 2.41%
  3. Adage Capital Partners GP L.L.C. — 1.55%
  4. 683 Capital Management LLC — 0.78%
  5. Millennium Management LLC — 0.64%
  6. Renaissance Technologies LLC — 0.63%
Learn More about top institutional investors of Immunic stock.

Which institutional investors are selling Immunic stock?

During the last quarter, IMUX stock was sold by these institutional investors:
  1. Adage Capital Partners GP L.L.C.
  2. Janus Henderson Group PLC
  3. Two Sigma Investments LP
  4. Marshall Wace LLP
  5. Jane Street Group LLC

Which institutional investors are buying Immunic stock?

During the previous quarter, IMUX stock was purchased by institutional investors including:
  1. Millennium Management LLC
  2. Renaissance Technologies LLC
  3. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
  4. Barclays PLC
  5. HB Wealth Management LLC
  6. Citadel Advisors LLC
  7. Invesco Ltd.
  8. Focus Partners Wealth
In the last year, these company insiders have bought Immunic stock:
  1. Richard Alan Rudick (Director)
  2. Glenn Whaley (CFO)
Learn More investors buying Immunic stock.